A Double-blind, Randomised, Placebo-controlled Study to Evaluate Three Doses of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs HDM SPIRE (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Circassia
- 12 Sep 2013 Results published in a Circassia Media Release.
- 12 Sep 2013 Primary endpoint 'Total-Rhinoconjunctivitus-Symptom-Score' has been met.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History